Medtronic's DBS Epilepsy Therapy Reduces Seizures 68% At Three Years
This article was originally published in The Gray Sheet
Executive Summary
Epilepsy patients treated with Medtronic's DBS deep brain stimulation therapy had a 68% median reduction in the frequency of seizures at three years compared to baseline, according to data released Dec. 6
You may also be interested in...
New Avenues in Neuromodulation
Implantable neurostimulation devices have the potential to ameliorate a number of debilitating conditions in which neural pathways play a role. Combined, these applications are expected to bring in device revenues of nearly $1.4 billion in the US alone in 2010, and that number is forecast to increase by double-digits going forward, reaching over $2.6 billion by 2014, according to Medtech Insight's recently published report, "US Markets for Neurostimulation Products."
New Avenues in Neuromodulation
Implantable neurostimulation devices have the potential to ameliorate a number of debilitating conditions in which neural pathways play a role. Combined, these applications are expected to bring in device revenues of nearly $1.4 billion in the US alone in 2010, and that number is forecast to increase by double-digits going forward, reaching over $2.6 billion by 2014, according to Medtech Insight's recently published report, "US Markets for Neurostimulation Products."
Medtronic Aims For Epilepsy DBS Implant Approval By Summer
Medtronic is aiming for PMA approval of its deep brain stimulation implant for epilepsy by next summer, despite a recent delay in a scheduled FDA advisory panel review of the device